PYC Therapeutics is an Australian drug-development company, which offers a new generation of RNA therapeutics to meet unmet needs in disease. It develops intracellular biological therapeutics including its own preclinical oncology payloads, using its proprietary cell Functional Penetrating Phylomers. It is one of the many ASX healthcare stocks that have performed exceptionally well off late PYC Therapeutics shares have returned over 135% over the last 12 months and it is currently trading at $0.145 a share.
Earlier today, PYC Therapeutics announced that its lead candidate – VP-001, for the treatment of RP11has restored function of the Retinal Pigment Epithelium, the target cells for the therapy, in patient-derived models of the disease. The result shows key improvement in the conviction of the lead candidate as PYC Therapeutics now heads towards clinical testing.
This achievement differentiates PYC’s RNA approach from Adeno-Associated Virus (AAV) delivered DNA therapies directed towards the treatment of RP11 that have not been able to demonstrate an improvement in these functional end-points in non-clinical testing.
Looking for Growth Stocks?
Growth stocks are potentially one of the hardest to pick as there are a lot of factors that need to be considered – from industry tailwinds to financial health of the individual stocks, and a lot of little things in between them. Shares in Value research team have picked their top 3 ASX stocks to buy in 2021. Click here to download the report for free.
